Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Search Science Hub
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
EASL 2026
Efficacy and safety of semaglutide 2.4 mg in the Japanese subgroup of the ESSENCE study
EASL 2026
EASL 2026
28 - 30 May 2026
Efficacy and safety of semaglutide 2.4 mg in the Japanese subgroup of the ESSENCE study
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Share
Copy link
{{pageUrl}}
Keywords
MASH
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)
